Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results

ABSTRACT: Key Points • The best response rates were observed with pembrolizumab before tisagenlecleucel; however, definitive conclusions cannot be made.• Pembrolizumab did not augment the cellular expansion of tisagenlecleucel but delayed peak expansion in the day 1 cohort. Abstract Tisagenlecleucel demonstrated high response rates and a manageable safety profile in adults with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) in the JULIET trial. However, lack of response and chimeric antigen receptor (CAR) T-cell exhaustion were observed in patients with programmed cell death protein 1 (PD-1) overexpression. Hence, pembrolizumab, a PD-1 inhibitor, was hypothesized to improve efficacy and cellular expansion of CAR T-cells in vivo. Here, we report the final analysis of the PORTIA trial i

SUBMITTER: Jaeger U 

PROVIDER: S-EPMC10225880 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature